{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:25:15Z","timestamp":1793053515019,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004000","name":"Guangzhou Municipal Science and Technology Program key projects","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["202102010081"],"award-info":[{"award-number":["202102010081"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejphar.2025.177885","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T12:13:44Z","timestamp":1751544824000},"page":"177885","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["The effects of GLP-1 receptor agonists on body composition in patients with type 2 diabetes, overweight or obesity: A meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"1003","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7612-9392","authenticated-orcid":false,"given":"Jieying","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting Yat Patrick","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Shing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjia","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiying","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5198-6358","authenticated-orcid":false,"given":"Yingxue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Pt 10","key":"10.1016\/j.ejphar.2025.177885_bib1","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1093\/brain\/awp208","article-title":"Expression of neurotrophic factors in diabetic muscle--relation to neuropathy and muscle strength","volume":"132","author":"Andreassen","year":"2009","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.ejphar.2025.177885_bib2","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.clnu.2024.06.034","article-title":"Metabolic effects of very-low calorie diet, Semaglutide, or combination of the two, in individuals with type 2 diabetes mellitus","volume":"43","author":"Anyiam","year":"2024","journal-title":"Clinical Nutrition"},{"issue":"4","key":"10.1016\/j.ejphar.2025.177885_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2023.108436","article-title":"The effect of SGLT2 inhibitors, GLP1 agonists, and their sequential combination on cardiometabolic parameters: a randomized, prospective, intervention study","volume":"37","author":"Bechlioulis","year":"2023","journal-title":"J. Diabetes Complicat."},{"issue":"5","key":"10.1016\/j.ejphar.2025.177885_bib4","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00592-014-0638-3","article-title":"Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes","volume":"51","author":"Bi","year":"2014","journal-title":"Acta Diabetol."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177885_bib5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00125-019-05021-6","article-title":"Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation","volume":"63","author":"Bizino","year":"2020","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.ejphar.2025.177885_bib6","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/dom.12932","article-title":"Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity","volume":"19","author":"Blundell","year":"2017","journal-title":"Diabetes Obes. Metabol."},{"issue":"3","key":"10.1016\/j.ejphar.2025.177885_bib7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1507\/endocrj.EJ16-0449","article-title":"Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial","volume":"64","author":"Bouchi","year":"2017","journal-title":"Endocr. J."},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2025.177885_bib8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/dom.14200","article-title":"Evidence-based weight loss interventions: individualized treatment options to maximize patient outcomes","volume":"23","author":"Bray","year":"2021","journal-title":"Diabetes Obes. Metabol."},{"issue":"8","key":"10.1016\/j.ejphar.2025.177885_bib9","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.2337\/dc09-2361","article-title":"Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition","volume":"33","author":"Bunck","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2025.177885_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1106868","article-title":"Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: an open-label, parallel-arm, randomized, metformin-controlled trial","volume":"14","author":"Cai","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"7","key":"10.1016\/j.ejphar.2025.177885_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3042","article-title":"Obesity and diabetes-not only a simple link between two epidemics","volume":"34","author":"Chobot","year":"2018","journal-title":"Diabetes-Metabolism Research and Reviews"},{"issue":"5","key":"10.1016\/j.ejphar.2025.177885_bib12","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.soard.2021.01.031","article-title":"Improvement of glucose metabolism following rapid weight loss after bariatric surgery and its impact on reduction of visceral abdominal fat versus free fat muscle","volume":"17","author":"Cogollo","year":"2021","journal-title":"Surg. Obes. Relat. Dis."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177885_bib13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: revised European consensus on definition and diagnosis","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"issue":"10","key":"10.1016\/j.ejphar.2025.177885_bib14","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1210\/clinem\/dgab408","article-title":"Exenatide, Dapagliflozin, or Phentermine\/Topiramate differentially affect metabolic profiles in polycystic ovary syndrome","volume":"106","author":"Elkind-Hirsch","year":"2021","journal-title":"J. Clin. Endocrinol. Metabol."},{"issue":"2","key":"10.1016\/j.ejphar.2025.177885_bib15","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.fertnstert.2022.04.027","article-title":"Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study","volume":"118","author":"Elkind-Hirsch","year":"2022","journal-title":"Fertil. Steril."},{"issue":"2","key":"10.1016\/j.ejphar.2025.177885_bib16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jdi.12888","article-title":"Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: a randomized trial","volume":"10","author":"Feng","year":"2019","journal-title":"Journal of Diabetes Investigation"},{"issue":"1","key":"10.1016\/j.ejphar.2025.177885_bib17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/00002018-200831010-00005","article-title":"Orlistat-associated adverse effects and drug interactions: a critical review","volume":"31","author":"Filippatos","year":"2008","journal-title":"Drug Saf."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177885_bib18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1530\/EC-17-0327","article-title":"Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS","volume":"7","author":"Fr\u00f8ssing","year":"2018","journal-title":"Endocrine Connections"},{"key":"10.1016\/j.ejphar.2025.177885_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108487","article-title":"Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: a randomized placebo-controlled trial","volume":"170","author":"Guo","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"3","key":"10.1016\/j.ejphar.2025.177885_bib20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.diabres.2014.09.046","article-title":"Evaluation of exenatide versus insulin glargine for the impact on endothelial functions and cardiovascular risk markers","volume":"106","author":"Gurkan","year":"2014","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"8","key":"10.1016\/j.ejphar.2025.177885_bib21","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.2337\/diacare.27.8.1915","article-title":"The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes","volume":"27","author":"Harder","year":"2004","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.ejphar.2025.177885_bib22","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2337\/dc22-1710","article-title":"Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes","volume":"46","author":"Heise","year":"2023","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.ejphar.2025.177885_bib23","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.33457","article-title":"Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial","volume":"4","author":"Heymsfield","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ejphar.2025.177885_bib24","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ Br. Med. J. (Clin. Res. Ed.)"},{"issue":"9","key":"10.1016\/j.ejphar.2025.177885_bib25","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.2337\/db10-1462","article-title":"Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice","volume":"60","author":"Himeno","year":"2011","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.ejphar.2025.177885_bib26","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/jcsm.12434","article-title":"Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy","volume":"10","author":"Hong","year":"2019","journal-title":"Journal of Cachexia Sarcopenia and Muscle"},{"key":"10.1016\/j.ejphar.2025.177885_bib27","article-title":"Visceral fat correlates with insulin secretion and sensitivity independent of BMI and subcutaneous fat in Chinese with type 2 diabetes","volume":"14","author":"Huang","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"2","key":"10.1016\/j.ejphar.2025.177885_bib28","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/dom.12795","article-title":"Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial","volume":"19","author":"Ish\u00f8y","year":"2017","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2025.177885_bib29","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13048-015-0161-3","article-title":"Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study","volume":"8","author":"Jensterle","year":"2015","journal-title":"J. Ovarian Res."},{"issue":"5","key":"10.1016\/j.ejphar.2025.177885_bib30","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1210\/clinem\/dgz140","article-title":"GLP-1 analog modulates appetite, taste preference, gut hormones, and regional body fat stores in adults with obesity","volume":"105","author":"Kadouh","year":"2020","journal-title":"J. Clin. Endocrinol. Metabol."},{"issue":"3","key":"10.1016\/j.ejphar.2025.177885_bib31","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"18","key":"10.1016\/j.ejphar.2025.177885_bib32","doi-asserted-by":"crossref","first-page":"21962","DOI":"10.18632\/aging.203546","article-title":"Dulaglutide improves muscle function by attenuating inflammation through OPA-1-TLR-9 signaling in aged mice","volume":"13","author":"Khin","year":"2021","journal-title":"Aging (Albany NY)"},{"issue":"3","key":"10.1016\/j.ejphar.2025.177885_bib33","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s13340-024-00717-6","article-title":"Effects of dulaglutide and trelagliptin on beta-cell function in patients with type 2 diabetes: a randomized controlled study: DUET-beta study","volume":"15","author":"Kondo","year":"2024","journal-title":"Diabetology International"},{"key":"10.1016\/j.ejphar.2025.177885_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116150","article-title":"Efficacy and safety of GLP-1RAs for people with obesity: a systematic review based on RCT and Bayesian network meta-analysis","volume":"171","author":"Li","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.ejphar.2025.177885_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3292","article-title":"Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes","volume":"36","author":"Liu","year":"2020","journal-title":"Diabetes-Metabolism Research and Reviews"},{"issue":"1","key":"10.1016\/j.ejphar.2025.177885_bib36","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/pedi.12787","article-title":"Does obesity cause type 2 diabetes mellitus (T2DM)? Or is it the opposite?","volume":"20","author":"Malone","year":"2019","journal-title":"Pediatr. Diabetes"},{"issue":"8","key":"10.1016\/j.ejphar.2025.177885_bib37","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/oby.23481","article-title":"Effects of liraglutide on gastrointestinal functions and weight in obesity: a randomized clinical and pharmacogenomic trial","volume":"30","author":"Maselli","year":"2022","journal-title":"Obesity"},{"issue":"3","key":"10.1016\/j.ejphar.2025.177885_bib38","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00125-019-05065-8","article-title":"Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial","volume":"63","author":"McCrimmon","year":"2020","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.ejphar.2025.177885_bib39","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/dom.12797","article-title":"Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes","volume":"19","author":"Mensberg","year":"2017","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2025.177885_bib40","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/9426014","article-title":"Glucagon-Like Peptide-1 receptor agonist protects dorsal root ganglion neurons against oxidative insult","volume":"2019","author":"Mohiuddin","year":"2019","journal-title":"J. Diabetes Res."},{"issue":"8","key":"10.1016\/j.ejphar.2025.177885_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25084300","article-title":"Emerging therapeutic strategies in Sarcopenia: an updated review on pathogenesis and treatment advances","volume":"25","author":"Najm","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.ejphar.2025.177885_bib42","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1111\/jdi.13270","article-title":"Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: a randomized controlled study","volume":"11","author":"Nakaguchi","year":"2020","journal-title":"Journal of Diabetes Investigation"},{"issue":"Suppl. 4","key":"10.1016\/j.ejphar.2025.177885_bib43","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes. Metabol."},{"issue":"9","key":"10.1016\/j.ejphar.2025.177885_bib44","first-page":"595","article-title":"Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled","volume":"9","author":"Neeland","year":"2021","journal-title":"clinical trial"},{"key":"10.1016\/j.ejphar.2025.177885_bib45","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3389\/fphar.2020.00090","article-title":"Preventive effects of dulaglutide on disuse muscle atrophy through inhibition of inflammation and apoptosis by induction of Hsp72 expression","volume":"11","author":"Nguyen","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177885_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.101880","article-title":"Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism","volume":"80","author":"Nunn","year":"2024","journal-title":"Mol. Metabol."},{"issue":"11","key":"10.1016\/j.ejphar.2025.177885_bib47","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/CIRCRESAHA.120.316101","article-title":"Obesity phenotypes, diabetes, and cardiovascular diseases","volume":"126","author":"Piche","year":"2020","journal-title":"Circ. Res."},{"issue":"11","key":"10.1016\/j.ejphar.2025.177885_bib48","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001357","article-title":"Abdominal obesity and Association with atherosclerosis risk factors: the uberlandia heart Study","volume":"95","author":"Roever","year":"2016","journal-title":"Medicine"},{"issue":"5 Suppl. l","key":"10.1016\/j.ejphar.2025.177885_bib49","doi-asserted-by":"crossref","first-page":"990S","DOI":"10.1093\/jn\/127.5.990S","article-title":"Sarcopenia: origins and clinical relevance","volume":"127","author":"Rosenberg","year":"1997","journal-title":"J. Nutr."},{"key":"10.1016\/j.ejphar.2025.177885_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) editions","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177885_bib51","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12933-023-01765-z","article-title":"Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial","volume":"22","author":"Sandsdal","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"issue":"8","key":"10.1016\/j.ejphar.2025.177885_bib52","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1111\/dom.15113","article-title":"Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: a randomized trial in adults with obesity and prediabetes","volume":"25","author":"Silver","year":"2023","journal-title":"Diabetes Obes. Metabol."},{"issue":"15","key":"10.1016\/j.ejphar.2025.177885_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25158214","article-title":"Impact of selected glucagon-like Peptide-1 receptor agonists on serum lipids, adipose tissue, and muscle Metabolism-A narrative review","volume":"25","author":"Szekeres","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.ejphar.2025.177885_bib54","doi-asserted-by":"crossref","first-page":"377","DOI":"10.14740\/jocmr4987","article-title":"Oral semaglutide induces loss of body fat mass without affecting muscle mass in patients with type 2 diabetes","volume":"15","author":"Uchiyama","year":"2023","journal-title":"J. Clin. Med. Res."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177885_bib55","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12933-019-0890-5","article-title":"A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients","volume":"18","author":"van Eyk","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"issue":"4","key":"10.1016\/j.ejphar.2025.177885_bib56","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1210\/jc.2015-3906","article-title":"Mechanisms of action of liraglutide in patients with type 2 diabetes treated with high-dose insulin","volume":"101","author":"Vanderheiden","year":"2016","journal-title":"J. Clin. Endocrinol. Metabol."},{"issue":"12","key":"10.1016\/j.ejphar.2025.177885_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/nu14122414","article-title":"Once-Weekly semaglutide induces an early improvement in body composition in patients with type 2 diabetes: a 26-Week prospective real-life Study","volume":"14","author":"Volpe","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.ejphar.2025.177885_bib58","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9783859","article-title":"Effects of exenatide and humalog Mix25 on fat distribution, insulin sensitivity, and \u03b2-Cell function in normal BMI patients with type 2 diabetes and visceral adiposity","volume":"2020","author":"Wang","year":"2020","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.ejphar.2025.177885_bib59","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.2147\/DMSO.S425642","article-title":"GLP-1RA Liraglutide and semaglutide improves obesity-induced muscle atrophy via SIRT1 pathway","volume":"16","author":"Xiang","year":"2023","journal-title":"Diabetes, Metab. Syndrome Obes. Targets Ther."},{"issue":"4","key":"10.1016\/j.ejphar.2025.177885_bib60","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41366-019-0513-y","article-title":"Short-term GLP-1 receptor agonist exenatide ameliorates intramyocellular lipid deposition without weight loss in ob\/ob mice","volume":"44","author":"Xu","year":"2020","journal-title":"Int. J. Obes."},{"issue":"2","key":"10.1016\/j.ejphar.2025.177885_bib61","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/dom.14882","article-title":"Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy)","volume":"25","author":"Yabe","year":"2023","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2025.177885_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.923606","article-title":"GLP-1 RAs and SGLT-2 inhibitors for insulin resistance in nonalcoholic Fatty liver disease: systematic review and network meta-analysis","volume":"13","author":"Yan","year":"2022","journal-title":"Front. Endocrinol."},{"issue":"6","key":"10.1016\/j.ejphar.2025.177885_bib63","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1002\/hep.30320","article-title":"Liraglutide, Sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic Fatty liver disease","volume":"69","author":"Yan","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2025.177885_bib64","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ Br. Med. J. (Clin. Res. Ed.)"},{"key":"10.1016\/j.ejphar.2025.177885_bib65","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ Br. Med. J. (Clin. Res. Ed.)"},{"key":"10.1016\/j.ejphar.2025.177885_bib66","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12986-018-0295-6","article-title":"Effects of exenatide versus insulin glargine on body composition in overweight and obese T2DM patients: a randomized controlled trial","volume":"15","author":"Yin","year":"2018","journal-title":"Nutrition & Metabolism"},{"issue":"11","key":"10.1016\/j.ejphar.2025.177885_bib67","first-page":"982","article-title":"[The effects of liraglutide on body composition and muscle strength in adult obese patients with type 2 diabetes mellitus]","volume":"60","author":"Yu","year":"2021","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"10.1016\/j.ejphar.2025.177885_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.951570","article-title":"Effects of liraglutide or lifestyle interventions combined with other antidiabetic drugs on abdominal fat distribution in people with obesity and type 2 diabetes mellitus evaluated by the energy spectrum ct: a prospective randomized controlled study","volume":"13","author":"Yu","year":"2022","journal-title":"Front. Endocrinol."},{"issue":"3","key":"10.1016\/j.ejphar.2025.177885_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/nu15030556","article-title":"Effects of a dulaglutide plus calorie-restricted diet versus a calorie-restricted diet on visceral fat and metabolic profiles in women with polycystic ovary syndrome: a randomized controlled trial","volume":"15","author":"Zhang","year":"2023","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.ejphar.2025.177885_bib70","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12933-023-01876-7","article-title":"Normal-weight visceral obesity promotes a higher 10-year atherosclerotic cardiovascular disease risk in patients with type 2 diabetes mellitus-a multicenter study in China","volume":"22","author":"Zheng","year":"2023","journal-title":"Cardiovasc. Diabetol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925006399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925006399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:20:20Z","timestamp":1754007620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925006399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":70,"alternative-id":["S0014299925006399"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177885","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effects of GLP-1 receptor agonists on body composition in patients with type 2 diabetes, overweight or obesity: A meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177885","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"177885"}}